Experiences with
Small cell lung cancer33,947 public posts
Want to take advantage of all our features? Just log in!
or
Share your experience of early-stage non-small cell lung cancer
Have you had surgery or radiotherapy for early-stage non-small cell lung cancer within the past year?
Did you have you cancer treatment in England?
Are you available to take part in a 1-hour interview online, by phone or in person?
New approval for treatment of Small Cell Lung Cancer (SCLC)
Read the full FDA announcement here:https://go2.org/blog/fda-approves-imdelltra-tarlatamab-dlle-for-extensive-stage-small-cell-lung-cancer/
FDA Approves Imfinzi (durvalumab) as First-Line Therapy for Limited-Stage SCLC
Read the full FDA announcement: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer
Please join us next Tuesday, October 15th, for our Living Room discussion on Treating EGFR Mutated Non-Small Cell Lung Cancer
Join us for a conversation on how new targeted therapies and a greater understanding of tumor biology have advanced treatments for EGFR-mutated non-small cell lung cancer (NSCLC). First-generation targeted therapy drugs outperformed traditional chemotherapy, but new mutations led to resistance.
Estela's Story - Why Low-Dose Lung Cancer Screening Should Be Routine
In 2022, much to my shock, I was diagnosed with small cell lung cancer (SCLC). At the time, I had no idea what small cell lung cancer meant. Naively, I assumed that “small” meant insignificant. It was not insignificant.
Success in early stage sclc with imfinzi.
Thought this was as worth sharing here
https://www.cancer.gov/news-events/cancer-currents-blog/2024/small-cell-lung-cancer-imfinzi-increases-survival?cid=eb_govdel_cancerinfo
Some success in limited stage sclc.
https://www.cancer.gov/news-events/cancer-currents-blog/2024/small-cell-lung-cancer-imfinzi-increases-survival?cid=eb_govdel_cancerinfo
A Veteran’s Experience with Small Cell Lung Cancer (SCLC)
Read about Jim's story here: https://go2.org/blog/a-veterans-story-with-small-cell-lung-cancer-sclc/
FDA Approves Augtyro (repotrectinib) for Adults and Children with NTRK-Positive Solid Tumors
Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
FDA Approves Tepmetko (tepotinib) for People with Metastatic Non-Small Cell Lung Cancer with MET-Exon 14 Mutation
Food and Drug Administration (FDA) granted traditional approval of Tepmetko (tepotinib) for people living with metastatic non-small cell lung cancer (NSCLC) with a MET-Exon 14 mutation.